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Additive manufacturing/3D printing of medical devices is becoming more commonplace, a 3D printed drug is now
commercially available, and bioprinting is poised to transition from laboratory to market. Despite the variety of
technologies enabling these products, the US Food and Drug Administration (FDA) is charged with protecting and
promoting the public health by ensuring these products are safe and effective. To that end, we are presenting the
FDA’s current perspective on additive manufacturing/3D printing of medical products ranging from those regulated by
the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), and the
Center for Biologics Evaluation and Research (CBER). Each Center presents an overview of the additively manufactured
products in their area and the specific concerns and thoughts on using this technology in those product spaces.Introduction
Recently, additively manufactured/3D printed medical
devices have caught the world’s attention: a 3D-printed
bronchial splint saved a child’s life [1, 2], a 3D printed
cranial plate replaced a large portion of a patient’s skull
[3], a new artificial knee was personalized to fit the pa-
tient’s own anatomy [4], and a spine device was made
with complex internal architecture which was previously
impractical to produce [5]. All of these are medical de-
vices that have had profound effects on patient health
and well-being. The FDA has been able to review and
regulate these devices under existing regulations, by pro-
actively identifying similarities with existing technologies
and key differences that needed to be evaluated. For
medical product production, additive manufacturing
may offer an approach to make a device with complex
architecture (e.g. integral porous coatings or internal lat-
tice structure). Additionally, this technology has been
leveraged to manufacture devices for specific patient’s
anatomy (patient matching). While additive manufactur-
ing of medical products has only recently entered the
awareness of the mainstream media, the FDA’s Center
for Device and Radiological Health (CDRH) has
reviewed and cleared additively manufactured medical
devices for more than 10 years. Over this time, there has* Correspondence: matthew.diprima@fda.hhs.gov
1US Food and Drug Administration, Center for Device and Radiological
Health, Silver Spring, MD 20993, USA
Full list of author information is available at the end of the article
© 2016 Di Prima et al. Open Access This articl
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifbeen an increase in submissions utilizing this technology
across a number of product areas; not just in medical
devices but also including drugs and biologics. Recently,
FDA’s Center for Drug Evaluation and Research (CDER)
has approved a 3D printed drug and the Center for Bio-
logics Evaluation and Research (CBER) has had interac-
tions with stakeholders in the bioprinting field.
With the increase in utilization of additive manufac-
turing and the uncertainty of how the technology can
affect the safety and effectiveness of the products, inter-
est in additive manufacturing has significantly increased
at the FDA. This interest led to the formation of the
Additive Manufacturing Working Group to address these
uncertainties and other questions about the additive
manufacturing of medical products. The working group
held a public workshop on October 8–9, 2014 to obtain
input from stakeholders titled – Additive Manufacturing
of Medical Devices: An Interactive Discussion on the
Technical Considerations of 3D Printing [6]. The first day
of the workshop aimed to bring together industry, aca-
demia, experts in the field and early adopting clinicians to
discuss with the FDA the current state of the art for
additive manufacturing, current best practices for valid-
ation and verification, as well as the technical challenges
and associated solutions for additively manufacturing
medical devices. The second day focused on the future
use of bioprinting (3D printed tissue engineered biologics)
and pharmacoprinting (3D printed pharmaceuticals). This
editorial presents the current state of 3D printed medicale is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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and devices. The primary focus is on the medical device
industry, which have been early adopters. This editorial
also provides a description of the regulatory pathways
devices have taken and the regulatory considerations they
face. Lastly, the outcomes of the technical workshop are
presented, and how those technical considerations are
being addressed since the workshop.
Review
Printing patient specific anatomy
The one aspect of 3D printing that has had a more
immediate impact on the health care ecosystem has been
the use of 3D printed anatomic models. There have been
many publications regarding the use of printed anatomy
in surgical planning, as a supplement to pictures from
typical imaging modalities such as MRI, CT and X-Ray
[7–10]. These uses have been particularly helpful with
patients with unique anatomies, often in children who
require complex surgeries due to anatomic anomalies [8,
9]. The 3D model of the patient specific anatomy has
been reported by surgeons to better aid in visualization
of the anatomy in question, when used with traditional
images [11–13]. In this case, the 3D print is being used
as a visual aid, and is treated much in the same way as a
visible printed record of the anatomy (21 CFR 892.2040
Medical Image Hardcopy Device).
Software has been cleared through the 510(k) pathway
that allows for segmentation of 3D patient scans, for
example CT or MRI scans, to be converted to a 3D
representation of the anatomy. This type of file, such as
an STL, is similar to outputting an image as a PDF. The
software used to generate the 3D model of the patient
anatomy is evaluated by the FDA to assess the accuracy
of the 3D volume reconstructed from image slices; how-
ever, the printer used to print the 3D component is
outside of the scope of FDA review, much like an office’s
laser printer would be when printing a PDF image.
Prints of patient anatomy should be unaltered by the
software if they are intended to be used for diagnostic or
clinical purposes. If the patient’s anatomy is altered
through the use of software in any way and indicated for
diagnostic use, discussion with the Agency would be
recommended. If patient specific anatomy is printed and
then used specifically for designing a medical device (e.g.
surgical cutting guide or implant), then the entire
process, including the print, would be considered a
device specific tool and should be part of the device sub-
mission (§201(h) Federal Food Drug & Cosmetic Act).
Pharmacoprinting
FDA’s recent approval on a 3D-printed drug product in
August 2015 (SPRITAM®) introduced a new chapter in
pharmaceutical manufacturing for solid oral dosage form[14]. The principles of pharmacoprinting are essentially
the same as other 3D printing types of medical products
and can produce complex, personalized medicines on de-
mand [15]. Personalized medicine began with the genomic
revolution in the early 1990s [16], but current standard-
ized dosage forms and associated manufacturing methods
still have not achieved this objective. In addition, there are
regulatory, legislative and process hurdles in fabricating a
drug delivery system to meet the individual needs. Al-
though the very first pharmacoprinted product approved
by the FDA is a solid oral immediate release product, the
majority of 3D printing research for oral delivery has been
focused on controlled release, targeting and precise deliv-
ery for extremely low dose drugs. Like any other solid oral
dosage forms, a 3D printed drug product must also be
manufactured in accordance with current chemistry,
manufacturing and control (CMC) standards as set forth
in the 21 CFR 200 s & 300 s and other relevant guidance.
Bioprinting
While there are currently no FDA approved or cleared
biological products that incorporate additive manufac-
turing, the FDA, specifically CBER, has interacted with
individuals who are using additive manufacturing tech-
nologies to print biological materials. Bioprinting offers
many advantages over traditional tissue engineering
techniques. For example, cells and biomaterials can be
printed simultaneously with more precise spatial control
in order to produce constructs with desired properties.
Academic research published in the scientific literature
demonstrates that bioprinting is an emerging field with
a wide array of applications [17–20]. Specifically, addi-
tive manufacturing has been investigated for applications
related to cellular and tissue constructs such as skin,
cartilage, bone, nerve and blood vessels. However, appli-
cations related to bioprinting are largely still in the
research & development phase.
Medical device printing
Over the past decade CDRH has cleared dozens of addi-
tively manufactured devices through the 510(k) process
[21] and in a few cases has approved them through
emergency use [22]. While these devices were made using
a variety of additive technologies and cover a number of
device types, they can generally be separated into implant-
able and non-implantable devices and devices that are
patient matched or non-patient matched. In addition to
having the capacity to create patient-matched devices, addi-
tive manufacturing also provides the advantage of being
able to create complex architectures. For example, some
orthopedic implant manufacturers leverage this technology
to create a complex porous structure integrated with the
solid parts of the device (e.g. acetabular shell with integral
porous coating) and others are composed of porous or
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plantable devices such as joint replacements, cranial im-
plants, maxillofacial implants and restorative devices such
as dental crowns and bridges may also be matched to the
patient’s anatomy for a variety of clinical needs. Additive
manufacturing is also commonly used to manufacture
patient matched cutting guides/drill templates, which are
non-implantable products that are used during surgery (e.g.
for knee, ankle, shoulder and maxillofacial surgeries).
Most of the additively manufactured devices just de-
scribed have been reviewed as Class II devices through
FDA CDRH’s Premarket Notification (510 (k)) Program.
The classification regulations are based on the risks to
health for a device’s intended use and the level of control
necessary to provide for a reasonable assurance of the safety
and effectiveness of the devices. Depending on the device
type, the use of additive manufacturing may present
additional technical challenges in terms of manufac-
turing controls, device performance, biocompatibility
and sterilization, etc. It does not, in general, raise
new questions of safety or effectiveness. Therefore,
unless an additively manufactured device presents a
new or different question of safety or effectiveness
for its device type, the device would be classified into
the same regulatory class as other devices of that
type, regardless of manufacturing method.
There are a couple of points that the FDA would
like to clarify that are commonly misunderstood by
medical product device stakeholders, especially in
regard to additive manufacturing. First, there is often
a misunderstanding that FDA clears or approves
materials for various medical uses. Rather, CDRH
evaluates a material within the context of the
technological characteristics of the device along with
the intended use and determines if the device’s
intended use and technological characteristics (in-
cluding the materials) are substantially equivalent in
safety and effectiveness to a legally marketed device.
If so, FDA provides clearance to individual devices
for specific intended uses, not to materials for un-
specified intended uses. Devices containing new ma-
terials may be cleared through the 510(k) process
provided that the new material does not raise new
questions of safety or effectiveness and the submis-
sion demonstrates that the new material is at least as
safe and effective as those in an equivalent legally
marketed device. However, it may be helpful in a
submission to identify a predicate or previously ap-
proved device that incorporates the same material as
your device, as this comparison may help in your ef-
fort to demonstrate substantial equivalence. The con-
cept is the same for additively manufactured devices.
FDA can clear a specific device made by additive
manufacturing for a specific intended use but it doesnot separately clear or approve raw material stock,
final printed material or a printing process (e.g.
Ti6Al4V using electron beam melting) for unspeci-
fied uses. However, predicate devices using the same
additive manufacturing process may reduce a submis-
sion’s premarket burden by leveraging previously pro-
vided information or testing.
Second, another source of confusion that the FDA would
like to clarify is the concept of “custom” versus “patient
matched” devices. Colloquially, “custom device” has been
referred to as a device that is made specifically for one
application or in this context, a specific patient; however,
the use of “custom” has a specific regulatory definition in
Section 520(b) of the Federal Food, Drug and Cosmetic
Act (FFD&C Act), which is further discussed in FDA’s
Guidance titled “Custom Device Exemption – Guidance
for Industry and Food and Drug Administration Staff.” The
guidance provides definitions of terms used in the custom
device exemption, explains how FDA interprets the “5
units per year of a particular device type” language con-
tained in section 520(b)(2)(B) of the FD&C Act, describes
what information should be submitted in a Custom Device
Annual Report (“annual report”), and provides recommen-
dations on how to submit an annual report for devices
distributed under the custom device exemption. The guid-
ance states as follows:
“It is worth noting that FDA reviews, clears and
approves for marketing many patient-specific devices
(also referred to as patient-matched devices). Patient
-specific devices are, in general, ones in which ranges
of different specifications have been approved or
cleared to treat patient populations that can be
studied clinically. Premarket submissions for such
devices are sometimes referred to as “envelope”
submissions because their approval or clearance covers
the entire range of specifications data they contain to
support. The final manufacturing of these devices can
be delayed until physicians provide imaging data or
other information to the manufacturer to finalize
device specifications within cleared or approved
ranges. As a result, such devices are specifically
tailored to patients. For example, a manufacturer of
an ankle replacement device could submit a 510(k) to
cover a range of specifications for different system
components to accommodate multiple patients with
different anatomical characteristics. While some in
industry have sometimes colloquially referred to these
devices as “customized,” they are not custom devices
meeting the FD&C Act custom device exemption
requirements unless they comply with all of the criteria
of section 520(b). Marketing applications are required
for these device types because the devices and patient
populations can be defined and studied.” [23].
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tive manufacturing, this has not changed the regulatory
pathway for medical products that are reviewed by the
FDA. This not only applies to premarket review, but also to
manufacturing quality during production.
Unless specifically exempted, all devices, including addi-
tively manufactured ones, must comply with the same
manufacturing quality and compliance requirements under
21 CFR 820, also known as the Quality System regulations
(QSr), where current good manufacturing practice (cGMP)
requirements are set forth. The regulation applies to so
many different types of devices that it cannot prescribe
specific details for each process. Instead, it provides a
framework for manufacturers to establish and follow quality
systems that will help ensure their products consistently
meet applicable requirements and specifications. The re-
quirements in this part are intended to ensure that finished
devices will be safe and effective and otherwise in compli-
ance with the FD&C Act. Established medical device manu-
facturers will be familiar with typical methods used to meet
the QSr, but some of the practices may be new to start-up
companies or recent entrants to the medical device field.
Newcomers to the medical device manufacturing area
may find CDRH’s Division of Industry and Consumer Edu-
cation (DICE)1 a valuable resource. DICE was created
specifically to provide technical and regulatory assistance to
small manufacturers to help them comply with the regula-
tory requirements for medical devices. The Division also
assists large manufacturers, academia and research organi-
zations, consultants, attorneys, customs brokers, govern-
ment agencies, user facilities, individuals who invent or
market devices, among others. For questions relating to
biological products, CBER’s Manufacturer’s Assistance and
Technical Training Branch (MATTBB)2 is also a useful
resource. MATTBB provides training and assistance to
industry and responds to requests for information regard-
ing CBER policies and procedures. For questions related to
drug products, CDER’s Division of Drug Information (DDI)
3 is available to provide expert advice and guidance regard-
ing all aspects of the Center’s activities.
FDA’s 2014 workshop
FDA has shown through experience that additive manu-
facturing follows the same regulatory pathway and manu-
facturing requirements as non-additively manufactured
devices. However, just as each manufacturing method (e.g.
casting, injection molding, machining) have their own
specific technical aspects and considerations, so does
additive manufacturing. The 2014 Public Workshop
brought together a broad spectrum of stakeholders to
discuss these technical considerations. Discussions were
separated into 5 broad technical themes: (1) materials, (2)
validation for design, printing and post printing, (3) print-
ing characteristics and parameters, (4) physical andmechanical assessment of final devices, and (5) biological
considerations of final devices, including cleaning, sterility
and biocompatibility. To facilitate and provide perspective,
a panel of external experts held a moderated discussion
with the attendees on each theme, starting with several
seed questions from the FDA. Even though each theme
was discussed separately, there was a common understand-
ing that the final device quality and performance strongly
depended on the interplay between all the themes.
Several of the most critical factors to device quality rose
to the top: 1) Build orientation and location can affect final
device performance. Geometric features will often have
different mechanical and material properties based on their
location in the build volume and orientation of print. This
can be especially important with small features such as por-
osity or load bearing features. 2) Validation of additive
manufacturing systems in the location they will be used is
key to achieving success. Moreover, workshop experts
agreed that it takes one to two years of experience using a
specific process and printer combination to build confi-
dence in the procedures. There are many ways to perform
quality assurance as well. Some companies stated that they
only produced one model of a product per machine. Others
used process validation principles and advanced monitoring
or verification techniques to produce multiple models in
one machine. Whichever quality assurance protocols were
chosen, it was clear that every machine is different and
needs to be validated and monitored individually. 3) Patient
matching is one of the greatest design advances enabled by
additive manufacturing. It brings personalized medicine to
medical devices. Unlike traditional designs that can go
through a final design review once, these patient matched
devices are all slightly different. Instead of reviewing one
final design, the entire design envelope (i.e. the range of
each parameter that can be modified), patient-matching
processes and identification procedure must be completed.
4) Sterilization of additively manufactured devices is funda-
mentally no different than for other devices. Small design
features or internal structures may make location of test
samples more difficult. Cleaning on the other hand, can be
a challenge for additively manufactured devices with
complex or small structures. Powder bed and liquid bath
based systems all have residual raw material that must be
removed before the device can be used. Measuring when it
has been removed can be more difficult for parts with small
intricate features. After the initial cleaning, if any machining
or other manufacturing steps are taken, those residues must
also be removed from the same small, intricate spaces.
Many attendees, including those from other industries
agreed that these considerations are extremely important
when building an additively manufactured product but that
they do not create insurmountable problems.
While the workshop served as an important starting
point in the discussion on the technical considerations
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efforts have not ended with the workshop. Since last
October, the FDA has participated in a number of
conferences and forums discussing additive manufac-
turing [24, 25] and has continued the conversation
with specific stakeholders during the review of their
devices. From these interactions, along with research
efforts within CDRH, we have expanded our knowledge
base and research experience [26, 27]. FDA and device
manufacturers continue to work together to ensure new,
innovative and personalized devices can be safely and ef-
fectively made through additive manufacturing.
Conclusion
The FDA has continued its mission of ensuring patients
and providers have access to safe and effective medical
products while endeavoring to provide industry with a
predictable, transparent and efficient regulatory pathway
for additively manufactured devices. The Center for Drug
Evaluation and Research approved the first 3D printed
drug within the existing chemistry, manufacturing and
control standards that all other drug products are regu-
lated by. The Center for Devices and Radiological Health
have cleared additively manufactured devices for over a
decade within the existing medical device regulations. The
Center for Biologics Evaluation and Research and the
other Centers are following the literature closely and are
interacting with stakeholders to ensure that US patients
have access to innovative, safe and effective medical prod-
ucts as this technology expands.
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